O ver three decades of stem cell research are currently culminating in remarkable clinical results, highlighting not only the broad applicability of these approaches, but also the immense future prospects of cell and gene therapy using adult stem cells and somatic derivatives of pluripotent stem cells (PSCs). The combined disciplines of cell and gene therapy and tissue engineering, broadly known as regenerative medicine, have the potential to revolutionize the treatment of diseases and injuries. Such advanced therapy medicinal products (ATMPs) require rigorous scientific evaluation by regulatory agencies. Marketing authorization is only granted if the product can fulfill stringent requirements for quality, safety and efficacy 1 . The past decade has witnessed an exponential growth in clinical trials involving ATMPs. In a few instances, stem-cell-based therapies produced remarkable clinical results and had a striking impact on incurable diseases. However, in many cases, the scientific rationale and preclinical efficacy were unclear, and clinical trials were not efficacious-if not detrimental-for the patients 1 . The term 'regenerative medicine' is often loosely used to include cell-dependent, nonspecific, trophic, anti-inflammatory or immunomodulatory effects rather than bona fide regeneration of healthy tissue induced by stem cells or derivatives.
Thus, the complexity and diversity of stem-cell-based ATMPs create a need for close examination of human stem cells that are already used in clinical settings or are close to clinical trials ( Fig. 1) . A thorough analysis of the scientific rationale, experimental methods and results that underpin these trials will help to define general criteria that foster stem-cell-based regenerative approaches. In this Review, we focus on stem cell types and their derivatives with translational applications to date, including haematopoietic, epithelial, muscle-and tissue-specific stem cells and stem-cell-derived dopaminergic neurons. We further discuss the limitations of these treatments, ongoing challenges in the field that also include potentially harmful and unregulated procedures, and emerging opportunities.
Haematopoietic stem cells
Autologous or allogeneic HSC transplantation (HSCT) is a lifesaving procedure used after irradiation or chemotherapy. Therapyinduced cell loss is compensated by haematopoietic stem cells (HSCs), which repopulate the host bone marrow and regenerate the entire haematopoietic system. The first patients were treated in 1957 with intravenous infusions of bone marrow cells from a healthy donor following radiation and chemotherapy 2 . Another 20 years later, leukaemia was successfully treated 3 , largely through an improved understanding of graft-versus-host disease (GVHD). In 1968, the first successful bone marrow transplantation for an inherited disorder was achieved in a 5-month-old boy with severe combined immunodeficiency (SCID) 4 . Over the past 50 years, HSCTs have been performed in over 400,000 individuals, becoming a curative option for haematological malignancies and severe inherited and acquired disorders of the haematopoietic system 5 . In addition to the regenerative potential of HSCs, allogeneic transplantations to treat neoplastic disorders also exploit graft-versus-malignancy and graft-versus-infection responses, in some cases with supplementation of cellular and/or gene therapies to complement deficient haematopoietic functions 5 . Refinements of related procedures have reduced the risks of chemotherapeutic toxicity, infection and GVHD 5 . Nonetheless, allogeneic HSCT still represents a challenge for future progress in clinical medicine.
Over the past 20 years, ex vivo HSC gene therapy (HSC-GT) ( Fig. 2a) has emerged as an effective treatment modality for mono genic disorders, including primary immunodeficiencies, haemo globinopathies, and metabolic disorders with neurological involvement 6 . Being an autologous procedure, HSC-GT does not require a compatible donor and there is no risk of GVHD or rejection, which are advantages over HSCT. The first HSC-GT medicinal product, Strimvelis, was approved in 2016 in the EU for the treatment of SCID due to adenosine deaminase (ADA) deficiency 7 . Based on a clinical trials.gov survey, at least five other HSC-GT products are expected to be filed for registration in the EU and USA by 2020, and Pamela Gehron Robey 8, 9 Despite many reports of putative stem-cell-based treatments in genetic and degenerative disorders or severe injuries, the number of proven stem cell therapies has remained small. In this Review, we survey advances in stem cell research and describe the cell types that are currently being used in the clinic or are close to clinical trials. Finally, we analyse the scientific rationale, experimental approaches, caveats and results underpinning the clinical use of such stem cells.
Review ARticle
NatuRe Cell BIology and over 20 clinical studies are ongoing for various genetic diseases 6 . The success of this approach derives from the extensive clinical experience in HSCT and the ability to manipulate HSCs ex vivo and produce viral vectors that deliver the therapeutic gene to HSCs, permanently correcting HSCs and their progeny in the patient.
For the purpose of HSC-GT, autologous HSCs are collected from the patient's own bone marrow or peripheral blood after druginduced mobilization, enriched for HSCs by CD34
+ cell purification and engineered with the viral vectors (Fig. 2a) 
8
. Transduced cells are then re-infused at the end of the manipulation or after a cryopreservation step. The collection, transfer, processing, sampling and shipment of human biological materials involved in autologous HSC-based GT treatment is a complex process that needs to adhere to stringent quality standards and regulations. Thus, it requires strict coordination between the sponsor and/or license holder, the good manufacturing practice (GMP) production facility and the certified transplantation centers involved in HSC collection, preparative chemotherapy and HSC-GT administration. Patients are usually administered a conditioning preparatory regimen to deplete endogenous HSCs that can be adjusted by decreasing the dosage and/or the number of chemotherapeutic and immunosuppressant agents 9 . The use of a reduced intensity regimen was first introduced for HSC-GT to treat ADA-SCID 10 and subsequently expanded to other diseases, adjusting the conditioning regimen to the therapeutic target and disease. Since 2000, 27 ADA-SCID patients in Milan have been treated with HSCs engineered with a γ-retroviral vector encoding ADA (including five patients who received infusion of Strimvelis), and all of them are alive and well [11] [12] [13] . In the majority of patients, HSC-GT was sufficient as a single treatment to restore immune and metabolic functions 11, 12 .
With the exception of ADA-SCID, one severe limitation of HSC-GT based on γ-retroviral vectors was the development of haematological malignancies due to insertional mutagenesis driven by activation of cellular oncogenes from strong viral enhancers 14, 15 . This drawback prompted the development of self-inactivating lentiviral vectors in which the expression of the therapeutic transgene is driven by a promoter, ideally of cellular origin, placed in an internal position. Preclinical studies showed that lentiviral vectors have a safer integration profile and allow for effective gene transfer into the most primitive HSCs 8 . Over 150 patients affected by 9 different genetic diseases have been treated with lentiviral-engineered HSCs so far 6, 12, 16 . Engineered HSCs are engrafted long-term and express the therapeutic gene, achieving evidence of clinical benefit with a favourable safety profile. The majority of HSCs can now be engineered with lentiviral vectors when measured in the infused medicinal product, leading to gene correction in 80-90% and stable engraftment in bone marrow in vivo 17 . In a clinical trial for X-linked adrenoleukodystrophy, a disease characterised by demyelination and neurodegeneration, 15 out of 17 patients had stable neurological function more than two years after receiving gene therapy 18 . HSC-GT for early onset metachromatic leukodystrophy (MLD), a fatal lysosomal disorder involving the central and peripheral nervous system, resulted in high-level production of the therapeutic enzyme in HSCs and their progeny, in circulation and in the CNS 19 . Prevention of disease onset or halting of disease progression compared to that in untreated patients 18 was shown in 8 out of 9 treated MLD patients. Therapeutic benefit was associated with treatment in presymptomatic patients or in those in a very early symptomatic stage.
After the genotoxic adverse events observed in the first studies of immune deficiencies, approaches to improve safety based on selfinactivating retroviral or lentiviral vectors were successfully implemented 20 . In the case of Wiskott-Aldrich Syndrome (WAS), a severe disorder of immune cells and platelets, HSCs were transduced with a lentiviral vector bearing the WAS cDNA expressed under its own promoter. Interim results of three distinct clinical trials provided evidence of immunological improvement, with effective protection against infectious processes, autoimmune events and bleeding [21] [22] [23] . The path to successful correction of red blood cell disorders was more challenging because of initial difficulties in achieving erythroid-specific, regulated and sustained transgene expression. Interim reports of two phase I/II clinical trials showed that HSC-GT can reduce or eliminate the need for long-term red blood cell transfusions in patients with β-thalassemia 24, 25 . The two studies differed in the route of HSC administration (intravenous versus intrabone infusion to avoid trapping in filter organs), conditioning regimen and patients' age 25 . Proof of concept for successful gene transfer in sickle cell disease was shown in a patient who received HSCs transduced with a lentiviral vector encoding an anti-sickling β-globin variant 26 . Further encouraging results using lentiviral-engineered HSCs have been obtained in clinical trials for ADA-SCID 12 , chronic granulomatous disease and Fanconi anemia 6 . Genome editing approaches in HSC using site-specific endonucleases 27 are also progressing to clinical application for primary immunodeficiencies and haemoglobinopathies 6 . These methods could be useful for disorders that require strict regulation of gene expression, such as RAG1, RAG2 or CD40-ligand immune Insertion-site analyses enable efficient tracking of repopulating haematopoietic cell clones across different lineages and monitoring of their behaviour during prolonged follow-ups. These analyses demonstrated sustained long-term HSC marking and multilineage potential of lentiviral-transduced HSCs and gave insights into the number of long-term HSCs that participate in haematopoietic reconstitution after HSC-GT 19, 21 . Moreover, they showed the existence of distinct HSPC subtypes that contribute differently to early and late post-transplantation phases and identified hierarchical relationships between lineages 29 . In summary, thanks to the considerable knowledge accumulated in these years and the progress in gene-editing approaches, HSC gene therapy promises to become the medicine of the future for both severe conditions with unmet medical needs and milder diseases for which allogeneic bone marrow transplantation bears excessive risks.
epithelial stem cells
In 1975, the first human epidermal keratinocyte culture was established 30, 31 . Less than 10 years later, the lives of two children suffering from burns that covered more than 95% of their body surfaces were saved using grafted autologous keratinocyte cultures 32 . This stunning achievement heralded the age of regenerative medicine and highlighted the potential of new techniques to culture epidermal cell populations, including stem cells. To date, keratinocyte cultures have been used globally to treat an extensive number of patients with third-degree burns 33 . Even though they were not called stem cells at the time, the keratinocytes cultured in 1975 matched the definition of stem cells as we know them today. In subsequent work that included clonal analysis of primary epidermal cultures, three types of clonogenic keratinocytes were identified that can generate holoclones, meroclones and paraclones 34 . Keratinocytes that form holoclones possess all stem cell hallmarks and produce meroclones and paraclones with properties of transient-amplifying progenitors 33 . We now know that the + cell purification (2) cells are cultured ex vivo short-term and infected with a retroviral vector (gamma-retrovirus or lentiviral vector) (3) . At the end of the manufacturing process, cells can be cryopreserved or prepared immediately for reinfusion. Before reinfusion of the transduced HSPCs (medicinal product), the patient receives a chemotherapy regimen with one or more drugs at a variable intensity (4). The autologous HSPCs are usually reinfused into the patient intravenously, 1-2 days after the end of chemotherapy (5). Patients are followed for several years to monitor clinical outcome (6) . Insertions site analyses provide useful information on safety profiles and HSPC cell fate dynamics. b, Skeletal stem cells (SSCs) are a subset of bone marrow stromal cells (BMSCs), found as pericytes on the abluminal side of marrow sinusoids. In vivo transplantation of SSCs/BMSCs demonstrates their ability to reform pericytes (demonstration of self-renewal), and differentiate into bone, stroma that supports haematopoiesis and marrow adipocytes. When used in an in vitro pellet cell culture, they are able to form cartilage.
presence of holoclone-forming cells is an essential feature of epidermal grafts and is required for long-term epidermal renewal 33, [35] [36] [37] [38] . Failure to engraft is most likely caused by the loss of holocloneforming cells, for instance, due to inadequate culture conditions 33 . Similar approaches are used for cultures of ocular limbal cells, which include stem cells of the corneal epithelium [39] [40] [41] [42] [43] . Visual acuity depends on a clear cornea, stromal avascularity and epithelial integrity. Repair and renewal of the corneal epithelium are mediated by stem cells of the limbus, the narrow zone between the cornea and the bulbar conjunctiva 44 . Extensive chemical burns of the cornea can damage the limbus and lead to limbal stem cell deficiency (LSCD). This condition is characterised by neovascularization, chronic inflammation, stromal scarring, corneal opacity and overall decreased visual acuity due to an invasion of bulbar conjunctival cells 44 . An option to prevent the conjunctival overgrowth is to restore the limbus, for instance, by grafting limbal fragments taken from the uninjured eye in unilateral LSCD 45 . The finding that limbal cultures 46 include stem cells detectable as holoclones 39 fostered the therapeutic application of autologous limbal cultures to enable the full functional regeneration of the corneal epithelium. These procedures led to improved visual acuity in patients with unilateral LSCD and severe bilateral corneal damage 37, [47] [48] [49] (Fig. 3a ). An area of 1-2 mm 2 of healthy limbus in an eye is enough to generate limbal cultures that allow the restoration of the corneal epithelium of both eyes 37, 49 . Colony size, epithelial cell growth rates and number of limbal clonogenic cells are not able to predict clinical outcomes 49 , indicating that the bulk of clonogenic keratinocytes likely behave as transient progenitors. Evidence also suggests that transient progenitors adjacent to epidermal stem cells promote adequate stem cell function, particularly during tissue regeneration 50 . The discovery of the transcription factor p63 as an important regulator in squamous epithelia further helped in the establishment of criteria to measure stem cell content in limbal cultures [51] [52] [53] [54] . In particular, the ΔNp63α isoform indicates the proliferative capacity of epithelial stem cells 54 . Expression decreases during clonal transition from holoclone to meroclone and is lacking in paraclones 55, 56 . Measurements of ΔNp63α abundance in holoclones can be used to estimate the number of stem cells in a limbal culture 57 . Strikingly, successful application of limbal cultures in the clinic correlated with a defined percentage of p63 bright holoclones 37, 49 .
As of yet, no correlation with clinical success or long-term (20 years of follow-up) corneal stability has been found for other suggested limbal stem cell markers 33, 58, 59 . Although the regeneration of the avascular corneal epithelium alleviates symptoms (burning, pain, and photophobia), full recovery of visual acuity in patients with stromal scarring requires a keratoplasty, which would not be successful in the absence of a functional, fully restored corneal epithelium 37 . In 2015, autologous limbal cultures were the first stem-cellbased ATMP to receive marketing authorization from the European Medicine Agency (Holoclar). Many other groups worldwide have used limbal cultures to treat ocular burns, often with different culture systems 33, 58, 59 . Measurement of the correlation between epithelial clonal types and clinical outcomes was not performed in any of those studies. Epithelial regeneration in skin and ocular burns using keratinocyte cultures provided only indirect, though compelling, evidence for the identification of holoclone-forming cells as longlived stem cells sustaining human squamous epithelia. The formal (2) are cultivated and used to prepare autologous fibrincultured grafts (3) . Grafts are then applied on the corneal surface of injured eyes (4) after removal of the the fibrovascular tissue with overlying pannus of abnormal conjunctival epithelium. Within one week after grafting, the corneal surface is covered with a transparent fully functional corneal epithelium (5). Long-term (over 20 years) follow-ups have confirmed stability and self-renewal capacity of the regenerated epithelium in hundreds of patients 37, 49 . b, Recently 38 , the entire epidermis of a child who had lost 80% of his skin owing to LAMB3-dependent epidermolysis bullosa (1) has been regenerated by transgenic (2) clonogenic keratinocytes (3), able to generate cohesive sheets of transgenic, autologous cultured epidermis (4). The transgenic epidermis was formed by holoclones, meroclones and paraclones (3 and 4) . Clonal tracing experiments demonstrated that the trangenic epidermis was sustained only by long-lived self-renewing stem cells (holoclones), generating pools of short-lived progenitors (meroclones and paraclones) (5) . The image in b was adapted by permission from Springer Nature: Nature, Gene Therapy: Transgenic stem cells replace skin, Aragona, M. and Blanpain, C. (2017).
proof came from combined ex vivo cell and gene therapy 30 years after the first clinical application of epidermal cultures 38 . Epidermolysis bullosa is a rare inherited disorder of the integuments. Four main types of the disease exist, which differ in severity and prevalence: epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), dystrophic epidermolysis bullosa (DEB), and Kindler syndrome 60 . JEB originates from mutations in three genes (LAMA3, LAMB3 or LAMC2) that jointly encode laminin 332 (also referred to as laminin 5) and in genes that encode collagen XVII or for α6β4 integrins 60 . The complete absence of laminin 332 is typically lethal early in life 60 . In non-lethal generalized JEB, laminin 332 is substantially decreased and hemidesmosomes are underdeveloped or absent. These deficiencies result in blisters and erosions of the skin and mucosa within the lamina lucida of the basement membrane in response to minor trauma. Extensive chronic skin wounds are detrimental to the patients' quality of life and result in recurring infections and scars. Furthermore, individuals with generalized recessive DEB and JEB are prone to developing aggressive squamous cell carcinomas as the disease progresses. No cure exists for JEB to date 60, 61 . Autologous, stem-cell-containing epidermal cultures were first transplanted to treat LAMB3-deficient JEB. Cells were genetically modified using a γ-retroviral vector (γRV) expressing full-length LAMB3 cDNA under the control of the Moloney leukaemia virus long-terminal repeat 62, 63 . Recently, such combined ex vivo cell and gene therapy has proved to be life-saving, as it achieved regeneration of the entire epidermis of the patient, a seven-year-old child suffering from a devastating form of JEB with poor prognosis 38 ( Fig. 3b) . At the last follow-up, the patient's transgenic epidermis expressed normal levels of laminin 332 and had normal thickness and morphology of hemidesmosomes and an intact basement membrane 38 . Of note, the absence of clonal selection in the transgenic epidermis was confirmed both in vitro and in vivo 38 . The three patients with JEB that were treated with γRV-transduced epidermal cultures received ~4 × 10 8 transgenic clonogenic keratinocytes and did not manifest tumour development or other adverse events (3.5-13 years follow-up) 38, 62, 63 . A similar γRV vector was in use for phase I and II clinical trials on recessive DEB 64 . Nevertheless, as with HSCs, the development of safer viral vectors is desirable for epidermal cultures.
Similarly to HSCs, clonal tracing experiments, using retroviral integrations as clonal genetic marks, answered the question as to whether the mammalian epidermis is sustained by a population of equipotent progenitors that directly, and perhaps stochastically, generate differentiated cells during the lifetime of the animal 65 or by long-lived stem cells that establish pools of short-lived progenitors 66 . The patient's transgenic epidermis unambiguously proved three premises. First, holoclone-forming cells, but not meroclones and paraclones, are able to extensively self-renew, both in vitro and in vivo. Second, meroclones and paraclones are transient progenitors that are progressively lost within a few months after transplantation. Third, the human epidermis is sustained by a limited number of long-lived stem cells (holoclones) that generate short-lived progenitors. These progenitors continue for some time, replenish differentiated cells and can contribute to wound healing for a short duration 38 ( Fig. 3b) . It would be of great interest to establish whether all holoclone-forming cells are identical or if a hierarchy exists amongst them.
For this reason, the most important attribute of a cultured epithelial graft is the presence and maintenance of an adequate number of stem cells detected as holoclones. This criterion is of paramount importance to ensure graft quality and increase the likelihood of a successful treatment. Hence, it should be carefully evaluated before a newly developed keratinocyte culture system is transitioned into a clinical setting. The knowledge and experience acquired in decades of research on epithelial stem cells and their clinical application is currently driving several clinical trials tackling different forms of epidermolysis bullosa.
Striated muscle stem/progenitor cells
Despite a number of structural and functional similarities, skeletal and cardiac muscle differ in their embryological origins 67, 68 and regeneration potency 69 . In mammals, skeletal muscle robustly regenerates after acute and chronic injury 70 , whereas cardiac muscle does not (or does so to a negligible extent) 71, 72 , beyond the first days of post-natal life 73 . From this observation it may be that skeletal muscle contains stem cells, but cardiac muscle does not. Although this is likely the case, we still know little, especially about the heart, and any clinical use of so-called 'stem cells' in diseases of skeletal and cardiac muscle has resulted in a negative outcome 74 . In the case of skeletal muscle, the bona fide stem cell is the satellite cell, first described by Mauro in 1961 75 . Satellite cells can be defined by their position between the muscle membrane and the basal lamina and by expression of the paired-ruled gene Pax7. Conversely, the paralogue Pax3 is predominantly expressed in satellite cells of the foetus and certain adult muscles 76 . Satellite cells contribute to postnatal muscle growth and, with sexual maturity, enter quiescence. Upon injury they are reactivated and contribute myogenic cells to muscle-fiber repair or replacement, as well as new stem/progenitor cells 77 . Satellite cells are currently the subject of intense investigation, focused mostly on their role in regeneration and senescence. Satellite cell origin and their role in postnatal growth are much less studied. Even though serial transplantation experiments established their stemness in mouse cells 78 , human cells have limited selfrenewal ability, as demonstrated by their exhaustion in more severe forms of muscular dystrophies with repeated degeneration-regeneration cycles 79 . In the 1990s, following successful transplantation of satellite cells into mouse muscle 80 , several clinical trials were carried out for cell transplantations in Duchenne muscular dystrophy (DMD) 81 . After in vitro expansion, satellite-cell-derived progenitors were directly injected into a small number of patient muscles, with no toxicity or efficacy even though donor nuclei and donor dystrophin were detected in the individuals 82 . Failure to engraft due to the death of transplanted cells and little migration from the injection site makes intramuscular transplantation of large muscles extremely challenging, if at all possible 83 . More recently, intramuscular injection into the pharyngeal muscles brought about some clinical benefit in people affected by oculopharyngeal muscular dystrophy, which causes progressive difficulty in swallowing 84 . Other clinical trials using satellite-cell-derived progenitors are ongoing for local damage to muscle, such as sphincter incontinence 85, 86 . Trials report some clinical benefit 87 , but outcome measures and study designs are not easy given the heterogeneity of patient populations and the varying severity of these lesions. In addition to satellite cells, skeletal muscle contains many other cell types, some initially identified by classic histology (fibroblasts, vessel pericytes, smooth muscle, endothelium, Schwann cells and tenocytes) and some more recently identified by the expression of specific markers such as Pw1 (PW1
− interstitial cells (PICs) 88 ) or PDGFRα (fibro-adipogenic progenitors 89 ). None of these cells have been characterised as stem cells, and they likely are not, but some may participate in muscle growth or regeneration. Mesoangioblasts are in vitro counterparts of muscle perivascular cells 90 that express tissue non-specific alkaline phosphatase (TNAP). Through the use of a TNAP-Cre mouse, mesangioblasts were shown to contribute to a limited extent to muscle growth and regeneration 91 . Human mesoangioblasts were intra-arterially transplanted into patients with DMD (because of their ability to cross inflamed vessel walls) in a trial that confirmed their safe use but lacked clinical efficacy, probably owing to very low engraftment levels 92 . Low survival, consequently poor engraftment and low migration are all issues that need to be resolved before clear clinical efficacy can be reached. Nevertheless, poorly controlled clinical trials continue, often on a commercial basis, and cause emotional and economical damage to DMD families.
In the case of cardiac stem cells, about 20 years of work, both in preclinical models and clinical trials, with different cell types and cardiac pathologies (though mainly myocardial infarction) generated a huge number of reports (for a meta-analysis, see ref. 93 ). Recently, a commentary presented a critical view on the experimental work that had served as a basis for many clinical trials 74 . Cardiac diseases typically have a much higher incidence than skeletal muscle diseases. In 2001, a controversial paper showed efficient cardiac regeneration following transplantation of bone marrow cells after myocardial infarction 94 . Other laboratories were unable to reproduce these data, with a growing consensus that the beneficial effect of cell transplantation, at best modest and transient, is likely due to secretion of paracrine factors that may promote cardiomyocyte survival and/or angiogenesis 95 . The same explanation seems to apply for most cell types transplanted into the infarcted heart, including different progenitor cells isolated from the heart itself on the basis of markers such as cKit, Islet-1 and Sca-1, to name a few examples 96, 97 . Another elegant and rigorous study, in which cardiac and non-cardiac cells were double labelled, demonstrated that cardiac cells readily generate non-cardiac cells during development, but this does not occur in the adult, even after injury 98 . Cardiac progenitors, derived from reprogrammed or embryonic stem cells (ESC), have been tested only in animal models to date; however, their differentiation into cardiac cell types seems more controlled 99, 100 , and their contribution to the regenerating myocardium is far more significant 101 . Extensive rebuilding of the myocardium has been achieved using human ESC-derived cardiomyocytes in primate hearts 102 , though applying this strategy in patients would still require substantial in vitro cell expansion and life-long immune suppression. In addition, newly generated cardiomyocytes are embryonic in size (one third of the adult size), and this limitation may easily cause arrhythmias 103 . A different route, tested only preclinically to date, is to avoid cell transplantation 104 and promote regeneration using different strategies. One option would be to activate endogenous cardiac progenitors in situ (if they exist) or trans-differentiate resident fibroblasts into cardiomyocytes through delivery of cardiac master genes 105 . Other strategies might include the application of external cardiac patches 106 or the induction of partial reprogramming in situ 107, 108 , assuming that incomplete reprogramming does not erase cell identity, which would lead to an expansion of immature cells that could differentiate into cardiomyocytes and vascular cells.
In conclusion, despite much experimental and clinical work, we still know relatively little about striated muscle stem/progenitor cells, and future clinical trials will certainly benefit from a deeper understanding of these cells and their regenerative potency.
tissue-specific stem/progenitor cells
The term "mesenchymal stem (stromal) cell" is broadly used and has come to mean any adherent fibroblastic population of cells, even those that are not stem cells based on rigorous criteria 109, 110 . The term was based on the pioneering work by Friedenstein and Owen (reviewed in ref. 111 ), who first described a population of clonogenic, non-hematopoietic bone marrow stromal cells (BMSCs) that were able to recreate cartilage, bone, haematopoiesis-supporting stroma and marrow adipocytes (now termed skeletal stem cells, SSCs 112 ) on the basis of in vivo transplantation studies. Due to their multipotency, it was speculated that these cells could form other mesodermal connective tissues outside their lineage (muscle, tendon, ligament, adipose tissue and others). For this reason, they were renamed "mesenchymal stem cells" 113 . However, this term is biologically incorrect for two reasons. The mesenchyme is an embryonic connective tissue that gives rise to connective tissues, blood and blood vessels. No postnatal stem cell has this ability (https:// embryo.asu.edu/pages/mesenchyme). Second, different connective tissues derive from different specifications of neural crest and mesoderm cells 114 (Fig. 2b) . No common "mesenchymal stem cell" exists during development or in the postnatal organism.
Despite the ambiguous identity of "mesenchymal stem cells" from different tissues and an inadequate understanding of their functions in most cases, ongoing efforts are made to use these cells in a clinical setting 115 . A serious development in recent years was the highly questionable use of uncharacterised cells in unregulated procedures that sometimes had harmful consequences for patients 116 . In regenerative medicine, "mesenchymal stem cells, " now renamed "medicinal signalling cells, " 117 are being used to treat a long list of diseases and disorders based on their putative paracrine, immunomodulatory and immunosuppressive effects. So far, over 900 clinical trials are officially registered, many without a reasonable basis (https:// clinicaltrials.gov/). Studies indicate that upon systemic infusion or direct injection, these cells rapidly disappear 118 . The rationale for their use and mechanism of action are equally unclear 119 . Labelling these treatments as 'stem cell' therapies is highly misleading without evidence that paracrine or immunomodulatory effects originate from a stem cell subset. Any putative effect is based on the effects of the entire population of cells, most of which are not stem cells. Even though some clinical studies using "mesenchymal stem cells" or "medicinal signaling cells" are indicated as safe, results for the majority of trials listed are unavailable. Based on a handful of published studies, outcomes have often failed to meet expectations. For example, a recent study utilizing 'cardiopoietic' cells derived from "mesenchymal stem cells" failed to show improvement of advanced ischaemic heart failure 120 . Likewise, a study using fat-derived "mesenchymal stem cells" failed to demonstrate closure and healing of perianal fistulas 121 , although some suggest that more encouraging results were reported from a better designed clinical trial 115 . However, the magnitude of the improvement, its persistence and potential mechanisms are not well known at this time.
In addition to clinical trials, large numbers of people pay for unregistered treatments in private clinics around the world without approval from regulatory bodies 122 . Many are using raw concentrates of whole bone marrow and liposuction aspirates. Detrimental adverse effects such as acute vision loss have been reported in patients treated for macular degeneration by bilateral, direct injection of liposuction aspirates 116 . These unfortunate cases highlight the urgent need to better educate the public, practicing physicians and also biomedical researchers about what "mesenchymal stem cells" are and how they can be used therapeutically in an appropriate and effective fashion. Importantly, clear guidance should be created on materials unsuitable for clinical use 122 . However, it is essential to note that bona fide tissue-specific stem/progenitor cells (TS/PCs) do exist in some tissues reported to contain "mesenchymal stem cells". We advocate that in any attempt to classify and define these populations, cells should be named after their tissue of origin and their differentiation capacity, as established by rigorous assays. In bone, skeletal stem cells are identified on the basis of their ability to generate cartilage, bone, stroma and marrow adipocytes 112, 114 (Fig. 2b) . In adipose tissue, TS/PCs should be called adipose stem/progenitor cells based on their ability to form adipocytes. Many tissues contain fibroblasts that have similar cell surface markers, but these markers are not specific and cannot be used to qualify any population of cells as stem cells as has been suggested 109, 123 .
In various human tissues, CD146
+ cells (negative for CD45 and CD31) are clonogenic, a feature common to many types of stem cells 124, 125 . Although cell-surface markers were nearly identical, transcriptome analyses and differentiation assays revealed marked differences in their CD146
+ cell inherent differentiation capacities 124 .
In addition, CD146
+ cells were, in fact, identified as pericytes, cells that wrap around nascent blood vessels and stabilize them 124, 126 . The pericytic nature of skeletal stem cells in bone marrow is supported by fate mapping of Lepr + cells in mice 127 . This intriguing finding supports the notion that the formation of pericytes in different tissues is a common developmental process, whereby in-growing blood vessels capture local cells at different stages of lineage commitment 110 . These cells remain quiescent on the blood vessel surface until activated by injury or during tissue remodelling and replenish the tissue of origin, but cannot transdifferentiate into functional cell types outside their lineage 110 . By contrast, a study that used Tbx18 as a pericytic marker did not identify pericytes in other tissues as resident progenitor cells 128 . Clearly, additional work is needed to test this hypothesis.
Albeit rare, some positive clinical examples for the application of TS/PCs to regenerate functional tissues exist. Quarto, Cancedda and coworkers have treated three people who have large bone defects with ex vivo expanded autologous SSCs/BMSCs with good results 129 , and a number of small studies followed 130, 131 . However, tissue engineering with SSCs/BMSCs has not become a mainstay in orthopaedics for a number of reasons, which include lengthy ex vivo expansion of autologous cells, the lack of weight-bearing scaffolds that support SSC and BMSC growth and differentiation and overall slow vascularization 132 . Likewise, stem cells within expanded autologous populations of the dental pulp were transplanted into pulpectomized teeth and could regenerate pulp and dentin based on radiographic evidence 133 . In these two studies, and contrary to the reports on ADA-SCID or epidermolysis bullosa 29, 38 , it was not possible to determine whether the regenerated tissue emanated from the exogenous cells because of a lack of markers. Nonetheless, these studies highlight that the functional capabilities of TS/PCs can be harnessed for therapy. Future studies will be essential to fully delineate these specific properties, which will undoubtedly lead to major advances in therapies based on appropriately characterised and verified stem cells.
PSC-derived cells in regenerative neuroscience
Cell replacement via transplantation of foetal cells has been developed as a therapeutic strategy to replace lost neurons in acute and progressive neurodegenerative disorders such as Parkinson's and Huntington's diseases, retinal degenerative disorders and stroke [134] [135] [136] [137] [138] [139] [140] . Although some of these studies have shown promising results, especially in Parkinson's Disease, they also highlight the difficulty of using foetal tissue as a cell source, and the necessity to develop readily available, bankable and quality-controlled cells for clinical use. Advances in PSC differentiation protocols have made the clinical use of PSC-derived cells feasible at a larger scale. Clinical trials have now been launched to treat spinal cord injury 141 . In ophthalmology, PSC-derived retinal pigment epithelial cells have been transplanted into patients with age-related macular degeneration 142, 143 (Fig. 4) . Both trials have confirmed the safety and feasibility of the method 142, 143 , and functional efficacy has been demonstrated in patients grafted with human ESC-derived retinal epithelial cells on a synthetic basement membrane 142 . These pioneering trials have served as a great encouragement and inspiration by providing important proof-of-concept data. They also guided the discussion of preclinical safety and tumourigenicity studies and thus paved the way for regulatory approval of other PSC-derived products in regenerative neuroscience targeted to neurodegenerative diseases. Here, we will focus on developments in the field of Parkinson's Disease, in which most foetal cell transplantation trials have been performed 135 , with stem cells now entering clinical trials 136 . Parkinson's disease is the second most common neurodegenerative disorder, characterised by a progressive loss of midbrain dopaminergic neurons, which results in reduced dopamine levels in the striatum that underlie the motor dysfunctions of the disease 144 . The most common treatment for Parkinson's disease today is increasing dopamine levels in the brain using dopaminergic drugs. Patients typically respond well to this treatment in the early stages of the disease, but prolonged medication, delivered in a nonphysiological and non-localized manner, is associated with adverse effects, such as dyskinesia and neuropsychiatric complications 145, 146 . Conceptually, cell-based therapy aims to replace lost dopamineric neurons with new healthy cells tasked to increase dopamine levels in a regulated fashion locally in the Parkinsonian striatum (putamen and caudate). The idea was first tested over 30 years ago by transplanting foetal ventral midbrain tissue into the putamen of patients with Parkinson's disease 147, 148 (Fig. 4) . Since then, a few hundred patients in Europe, the US and Canada have received foetal ventral midbrain transplants 135 . These trials have provided important evidence that restoration of dopaminergic striatal innervation can indeed provide long-term clinical benefits in patients with Parkinson's disease 135 . Outcomes of these trials, however, have been highly variable, and their fidelity has been questioned 135 . With time, it has become clear that some grafted patients have a substantial and long-term effect from their transplants 149 . These findings are in agreement with functional PET imaging demonstrating restored dopaminergic transmission, and postmortem analyses of brains decades after transplantation indicate long-term graft survival and extensive innervation of host putamen [150] [151] [152] [153] . At the same time, other patients showed no, or only modest, clinical improvements and side effects in the form of graft-induced dyskinesia have been observed in a significant number of patients 135 . Moreover, postmortem analysis revealed Lewy body pathology in the transplanted cells 153, 154 . Even so, preclinical and clinical work spanning over 30 years corroborate that regenerative transplantation therapy in Parkinson's disease is achievable. However, cell-based therapy using foetal cells is not a viable option for the future due to scarcity of donor tissue. An expandable source of cells that can be supplied on demand and in sufficient quantities is needed to circumvent the problems currently associated with foetal tissue grafting. The use of such cells will also provide better possibilities for standardization and quality control, which are needed for a more robust outcome in patients. The most obvious choice might be to expand cells from foetal ventral midbrain tissue prior to transplantation. However, it has proven difficult to sufficiently expand neural progenitors while maintaining their capacity to differentiate into authentic and functional dopaminergic neurons 155 . With the first report of human ESC cultures in 1998 156 , and human induced PSCs in 2007 157 , new possibilities for obtaining an unlimited source of dopaminergic neurons have become available. A number of early studies succeeded in generating neurons, including dopaminergic-like neurons from human ESCs 135 . In the early 2010s, protocols that mimicked the developmental trajectory of midbrain dopaminergic neurons reported the generation of authentic dopaminergic neurons of midbrain identity that survived, integrated and functionally matured in preclinical models of Parkinson's disease 158, 159 . Importantly, the stem-cell-derived dopaminergic neurons and their progenitors are molecularly and functionally similar to the cells from foetal ventral midbrain tissue [159] [160] [161] , providing evidence that these cells are of a quality needed for use in patients. These results enabled GMP adaptation and the development of cell manufacturing regimes for generating cryopreserved dopaminergic progenitors for use in clinical trials (Fig. 4) . These first-in-human, PSC-based trials were designed on the basis of important aspects learned from the foetal cell trials, conducted in 1980-1990, as well as the currently ongoing EU-funded multicenter foetal ventral midbrain transplantation trial TRANSEURO 135 . The knowledge gained has helped researchers decide on cell dosing, surgical parameters, patient selection, immune suppression and appropriate outcome measures in current trials, thereby increasing the chances of success.
It should be noted that a new level of complexity arises, related to the fact that stem-cell-derived products (unlike foetal cells) are regulated as ATMPs. Nevertheless, a number of centers around the world are now at the verge of entering clinical trials [162] [163] [164] . In this capacity, different groups have come together to jointly tackle issues related to preclinical assessments, manufacturing, safety and efficacy testing, and fast-track therapies on route to the clinic within a network called GForce-PD 136, 165 . These are exciting times in Parkinson's disease research and likely also spur the development of new regenerative approaches in other neurodegenerative diseases.
Conclusion
Almost 30 years of intense basic and clinical research were necessary to translate knowledge gained on haematopoietic and epithelial stem cells into defined and reproducible therapies that can cure or alleviate diseases. During the same timeframe, cell-based treatments for Parkinson's and retinal diseases have undergone a similar development. These achievements required in-depth knowledge of the biology of specific stem cells and their derivatives, of lineage relationships, cellular functions and signalling mechanisms in homeostasis and disease. However, their success also relied greatly on adequate and feasible clinical protocols. In the case of blood and squamous epithelia, protocols were relatively easy to develop: HSCs are delivered by intravenous infusion, whereas squamous epithelial cultures and retinal pigment epithelial cells require transplantation onto a properly prepared body surface. Somewhat more complex, CNS cell replacement requires neurosurgery and delivery methods that have been developed in parallel to cell generation. Translation of stem cell biology into clinical practice to treat complex, vascularized tissues or organs is intuitively much more multifaceted as well, owing to the difficulty in ablating the resident diseased cells, thus creating space for donor cell engraftment. Removal of diseased haematopoietic or skin stem cells is easily attained, but it would be cumbersome, for instance, in the skeleton or the muscle. The analysis of success or failure of stem-cell-based therapies will contribute to a deeper understanding of the biology of specific stem cells, as exemplified by trials with haematopoietic and epidermal stem cells.
The criteria developed in successful clinical applications of defined stem cells will provide blueprints that can be applied to other stemcell-based cell and gene therapies that are currently in development. 
